AR082625A1 - HUMANIZED ANTIBODIES AGAINST EGFR - Google Patents

HUMANIZED ANTIBODIES AGAINST EGFR

Info

Publication number
AR082625A1
AR082625A1 ARP110102913A AR082625A1 AR 082625 A1 AR082625 A1 AR 082625A1 AR P110102913 A ARP110102913 A AR P110102913A AR 082625 A1 AR082625 A1 AR 082625A1
Authority
AR
Argentina
Prior art keywords
seq
amino acid
acid sequence
egfr
heavy chain
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Steffen Goletz
Antje Danielczyk
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Priority to ARP110102913 priority Critical patent/AR082625A1/en
Publication of AR082625A1 publication Critical patent/AR082625A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Anticuerpos humanizados anti-EGFR que presentan propiedades de unión al antígeno similares a las del anticuerpo anti-EGFR murino o quimérico del que derivan. Anticuerpos humanizados anti-EGFR que son útiles en el tratamiento del cáncer.Reivindicación 1: Un anticuerpo humanizado, o un fragmento o un derivado de éste, caracterizado porque puede unirse a un receptor del factor de crecimiento epidérmico (EGFR) y que comprende una región variable de la cadena pesada donde la CDR1 tiene la secuencia de aminoácidos de SEQ ID Nº 1, la CDR2 tiene la secuencia de aminoácidos de SEQ ID Nº 2 y la CDR3 tiene la secuencia de aminoácidos de SEQ ID Nº 3, y donde una o más de las regiones del marco de trabajo 1, 2 y 3 corresponden a las regiones del marco de trabajo de una región variable de la cadena pesada secuencia de aminoácidos que comprende SEQ ID Nº 31.Humanized anti-EGFR antibodies that exhibit antigen binding properties similar to those of the murine or chimeric anti-EGFR antibody from which they are derived. Humanized anti-EGFR antibodies that are useful in the treatment of cancer. Claim 1: A humanized antibody, or a fragment or derivative thereof, characterized in that it can bind to an epidermal growth factor receptor (EGFR) and comprising a region heavy chain variable where the CDR1 has the amino acid sequence of SEQ ID No. 1, the CDR2 has the amino acid sequence of SEQ ID No. 2 and the CDR3 has the amino acid sequence of SEQ ID No. 3, and where one or more of the framework regions 1, 2 and 3 correspond to the framework regions of a variable region of the heavy chain amino acid sequence comprising SEQ ID No. 31.

ARP110102913 2011-08-10 2011-08-10 HUMANIZED ANTIBODIES AGAINST EGFR AR082625A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP110102913 AR082625A1 (en) 2011-08-10 2011-08-10 HUMANIZED ANTIBODIES AGAINST EGFR

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP110102913 AR082625A1 (en) 2011-08-10 2011-08-10 HUMANIZED ANTIBODIES AGAINST EGFR

Publications (1)

Publication Number Publication Date
AR082625A1 true AR082625A1 (en) 2012-12-19

Family

ID=47562089

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102913 AR082625A1 (en) 2011-08-10 2011-08-10 HUMANIZED ANTIBODIES AGAINST EGFR

Country Status (1)

Country Link
AR (1) AR082625A1 (en)

Similar Documents

Publication Publication Date Title
AR109715A1 (en) ANTI-CD27 ANTIBODIES
MY190771A (en) Anti-pd-l1 antibodies and uses thereof
AR106184A1 (en) PD-1 BINDING PROTEINS AND THEIR METHODS OF USE
CY1120414T1 (en) ANTIBODIES CONNECTED TO NO40 AND THEIR USES
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
MX2020001873A (en) Binding agents.
EA201791961A1 (en) ANTIBODIES SPECIFIC TO CD47 AND PD-L1
PE20190976A1 (en) ANTIBODIES OF UNION TO CD3
NZ610734A (en) Human antibodies to the glucagon receptor
PE20121649A1 (en) MONOCLONAL ANTIBODIES TO PROGASTRIN AND ITS USES
AR084210A1 (en) PROTEINS OF UNION TO TNF-a
PE20240218A1 (en) AFFINITY MATURED AND HUMANIZED ANTIBODIES TO FCRH5
AR099812A1 (en) ANTI-EGFR ANTIBODY AND DRUG ANTIBODIES AND CONJUGATES
PE20221580A1 (en) THERAPEUTIC ANTIBODIES AND THEIR USES
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
ES2776179T3 (en) Antibodies directed against surface determinants of S. aureus
NZ715896A (en) Humanized or chimeric cd3 antibodies
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
PE20141398A1 (en) NEUTRALIZING ANTIBODIES OF HUMAN CYTOMEGALOVIRUS
AR084141A1 (en) ANTI-CCL20 NEUTRALIZING ANTIBODIES
NZ631007A (en) Anti-c5 antibodies having improved pharmacokinetics
CO6430469A2 (en) HUMANIZED ANTIBODIES THAT JOIN CD19 AND ITS USES
CO6410312A2 (en) ANTIBODY MOLECULES THAT HAVE SPECIFICITY FOR HUMAN OX40
NZ605980A (en) Anti-fap antibodies and methods of use
AR096617A1 (en) ANTI-TWEAKR ANTIBODIES AND THEIR USES

Legal Events

Date Code Title Description
FB Suspension of granting procedure